<unk>  is a kinase inhibitor that is FDA approved for the treatment of metastatic non-small cell lung cancer (NSCLC).   Common adverse reactions include diarrhea, rash/dermatitis acneiform, stomatitis, paronychia, dry skin, decreased appetite, pruritus.
Afatinib
Neratinib
Dasatinib
Fostamatinib
Brigatinib
Acalabrutinib
Lenvatinib
Bosutinib